Wall Street brokerages expect Cytosorbents Co. (NASDAQ:CTSO – Get Rating) to report sales of $9.84 million for the current quarter, according to Zacks. Five analysts have made estimates for Cytosorbents’ earnings. The highest sales estimate is $10.30 million and the lowest is $9.16 million. Cytosorbents posted sales of $10.60 million during the same quarter last […]
Metropolitan Life Insurance Co NY bought a new stake in Cytosorbents Co. (NASDAQ:CTSO – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,670 shares of the medical research company’s stock, valued at approximately $95,000. Other hedge funds and other […]
CytoSorbents Gets FDA Approval To Conduct Trial; Shares Up morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Certain industries or groups, at times, get hit hard providing venturesome contrarian investors opportunities to earn outsized profits. Contrary investors with the courage and conviction to get into automotive and retailing shares at the depth of the Great Recession have made it out like a bandit.. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
52-week low: $3.60
Company Profile
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company s product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.